ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Miguel-Angel Perales, M.D., Named 2023 - 2024 President of ASTCT

New Board Members Announced at 2023 Tandem Meetings in Orlando, FL

Headshot of Miguel-Angel Perales, M.D.
Headshot of Miguel-Angel Perales, M.D.

2023 - 2024 President of ASTCT

The American Society for Transplantation and Cellular Therapy (ASTCT) announced Miguel-Angel Perales, M.D., as the President of the Society in 2023 - 2024. Dr. Perales first served on the Board of Directors in 2017 and has been a member of ASTCT since 2001.  

Dr. Perales is Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York and a Professor of Medicine at Weill Cornell Medical College. 

"I have enjoyed serving on the ASTCT Board of Directors, and I am honored to serve as President this year," stated Dr. Perales. "In my practice, my patients have a variety of hematologic malignancies and are in need of an allogeneic transplant or cellular therapy. The goal of my practice, research, and now as President of ASTCT is to further advocate for our patients and support our field by advancing the science and further providing educational opportunities for our members." 

Prior to his time on the ASTCT Board of Directors, Dr. Perales served on the Education Committee, and Committee for Practice Guidelines, and is the founding editor of the ASTCT Mobile App. As ASTCT president, Dr. Perales will direct the organization's new strategic plan, and continue to bring more science focus to ASTCT to help advance better treatment options for patients. 

He is the current Chair of the Alliance for Clinical Trials in Oncology Transplantation and Cell-Based Therapies Committee and has served as Vice-Chair and member of the Board of Directors of Be The Match (National Marrow Donor Program - NMDP). He has also held leadership positions in the Center for International Blood and Marrow Transplant Research (CIBMTR) and Blood and Marrow Transplantation Clinical Trials Network (BMT CTN).

Professionally, Dr. Perales is an expert in donor-derived hematopoietic stem cell transplantation and cellular therapy. He is currently participating in a number of studies designed to improve outcomes in patients undergoing stem cell transplantation, including looking at ways to lower the risk of complications, relapse, and graft-versus-host disease. He is also conducting translational clinical research to investigate new ways to enhance the recovery of the immune system after a transplant and ways to help the immune system fight hematologic malignancies. Dr. Perales has been published in more than 350 publications, including peer-reviewed articles, position papers, guidelines, editorials, invited reviews, and book chapters. 

In addition to Dr. Perales, below is the complete list of 2023 - 2024 ASTCT Board of Directors: 

  • Miguel-Angel Perales, M.D., (Memorial Sloan Kettering Cancer Center); President 
  • Corey Cutler, M.D., MPH, (Dana Farber Cancer Institute); President-Elect President 
  • David Porter, M.D., (University of Pennsylvania), Vice President
  • Brenda M. Sandmaier, M.D., (Fred Hutchinson Cancer Center); Past President
  • Uday Popat, M.D., MBA, (MD Anderson Cancer Center); Treasurer
  • Mehdi Hamadani, M.D., (Medical College of Wisconsin); Secretary
  • Betty Hamilton, M.D., (Cleveland Clinic); Director of Community or Clinical Practice
  • Nandita Khera, M.D., MPH, (Mayo Clinic); Director of Community or Clinical Practice
  • Dianna Howard, M.D., (Atrium Health Wake Forest Baptist); Director of Community or Clinical Practice
  • Brian Betts, M.D., (University of Minnesota); Director of Laboratory Science
  • Alan Hanash, M.D., Ph.D., (Memorial Sloan Kettering Cancer Center); Director of Laboratory Science                        
  • Sung-Yun Pai, M.D., (National Cancer Institute); Director of Laboratory Science    
  • Kirsten Williams, M.D., (Emory University School of Medicine); Director at Large 
  • Lori Muffly, M.D., MS, (Stanford University); Director at Large       
  • Nirali Shah, M.D., (National Cancer Institute); Director at Large       
  • Robert Korngold, Ph.D., (JTCT); Editor-in-Chief
  • Misty D. Evans, DNP, APRN, CPNP-AC, BMTCN, (Vanderbilt University/Sarah Cannon Pediatric Hematology-Oncology & Cellular Therapy at TriStar Centennial); Director of Advanced Practice Providers
  • Alison Gulbis, PharmD, BCOP, (The University of Texas MD Anderson Cancer Center); Director of Pharmacists

###

About American Society for Transplantation and Cellular Therapy (ASTCT) 

ASTCT is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education, and clinical practice in the field. For more information about ASTCT, visit www.astct.org and follow ASTCT on Twitter @ASTCT.

Contact Information:
Kate Purdy
ASTCT Senior Marketing Manager
kpurdy@astct.org
(202) 367-2387
Related Files
ASTCT Leadership 2023 - 2024 Announcement_FINAL.docx



Original Source: Miguel-Angel Perales, M.D., Named 2023 - 2024 President of ASTCT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.